Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Blount disease is characterized by disturbed growth of the inner portion of the upper tibial extremity, progressively leading to bowlegged deformity with bone angulation just below the knee (tibia varus). In 60% of cases, the condition affects both legs.
Features include very common findings: Tibial bowing; and common findings: Abnormality of the knee, Abnormal tibial metaphysis morphology, Abnormality of the proximal tibial epiphysis, and Osteochondrosis.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 1 | Osteochondrosis |
Phenotype severity distribution: 1 very common feature, 4 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
27 publications have been identified in PubMed for Blount disease. Research spans Case Report / Case Series (41%), Clinical Trial Publication (26%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 41% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:58 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Blount disease
Clinical study results |
7 |
26% |
Disease patterns and progression | 5 | 19% |
Research summaries | 4 | 15% |
Tageldeen Mohamed M (2026). [PMID: 41347460](https://pubmed.ncbi.nlm.nih.gov/41347460/). *J Pediatr Orthop*. [Clinical Trial Publication]
Jansen N (2026). [PMID: 41523661](https://pubmed.ncbi.nlm.nih.gov/41523661/). *JB JS Open Access*. [Epidemiology / Natural History]
Coskun E (2026). [PMID: 41178588](https://pubmed.ncbi.nlm.nih.gov/41178588/). *J Pediatr Orthop*. [Clinical Trial Publication]
Yuan Z (2026). [PMID: 42176602](https://pubmed.ncbi.nlm.nih.gov/42176602/). *Gait Posture*. [Clinical Trial Publication]
Asad N (2026). [PMID: 42170411](https://pubmed.ncbi.nlm.nih.gov/42170411/). *Pak J Med Sci*. [Case Report / Case Series]
Wang B (2025). [PMID: 40270720](https://pubmed.ncbi.nlm.nih.gov/40270720/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Trisolino G (2025). [PMID: 40869537](https://pubmed.ncbi.nlm.nih.gov/40869537/). *J Clin Med*. [Epidemiology / Natural History]
Özcabı B (2025). [PMID: 37855273](https://pubmed.ncbi.nlm.nih.gov/37855273/). *J Clin Res Pediatr Endocrinol*. [Case Report / Case Series]
Kim Y (2025). [PMID: 39461587](https://pubmed.ncbi.nlm.nih.gov/39461587/). *Orthop Traumatol Surg Res*. [Clinical Trial Publication]
Pan YT (2025). [PMID: 41233281](https://pubmed.ncbi.nlm.nih.gov/41233281/). *J Orthop Sci*. [Clinical Trial Publication]
AI-curated news mentioning Blount disease
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.